Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Nicotine swap helps smokers slash cigarettes in half

NCT ID NCT06554873

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether smokers who quickly respond to nicotine alternatives (like patches, e-cigarettes, or pouches) can keep smoking less or stop entirely for 6 months. 150 healthy adult smokers who reduced their smoking by at least half within 2 weeks were followed. The goal was to see if using these products long-term helps maintain lower smoking levels or quitting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

150 people

The number who actually took part.

Started

Aug 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy, adult smoker of combustible cigarettes. * Age 22 to 65 years at time of screening (verified by government issued ID). * Smoke cigarettes for ≥12 months prior to screening. * Currently smokes at least 10 tobacco cigarettes per day. * Screening eCO ≥ 10 ppm. * Voluntarily provides consent for participation by signing the informed consent form (ICF). * Willing and able to comply with study requirements. Exclusion Criteria: * Unable to read, speak or understand English * Has a history or presence of clinically significant medical or psychiatric disease, or any other condition that would in the PI's judgement jeopardize the safety of the participant, impair the participant's ability to comply with study procedures, or impact the validity of the study results. * Has used nicotine-containing e-cigarettes (or vapes) or any nicotine replacement therapy (nicotine patch, nicotine gum, nicotine spray, nicotine inhaler, nicotine lozenge) or prescription smoking cessation medications, including, but not limited to, varenicline (Chantix\*) or bupropion (Zyban®) within the past 30 days. If female, participant is pregnant, nursing, or intends to become pregnant during the time period from screening through the end of study. * Has participated in a research study about tobacco products or ENDS within the past 30 days. * Has participated in a smoking cessation or nicotine switching research study in the past year. * Smokes or vapes cannabis more than once a week. * Cannabis Use Disorder Identification Test-Revised (CUDIT-R) score of 8 or greater. * Heterosexually active participants of Childbearing Potential (not sterilized by tubal ligation, oophorectomy, hysterectomy, or other surgical methods, or post-menopausal) that do not agree to practice medically appropriate methods of birth control (or remain abstinent) during the course of the trial. Medically acceptable methods of birth control include: vasectomy, vaginal diaphragm with spermicide, intrauterine device, hormonal birth control (oral, injected, or implanted), condom with spermicide, or sponge with spermicide. * Subgroup enrollment is complete.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Harm reduction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Harm Reduction nicotine dependence Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rose Research Center

    Charlotte, North Carolina, 28262, United States

  • Rose Research Center

    Raleigh, North Carolina, 27617, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.